AKT1 and liver cancer: Bufalin also could enhance the anticancer efficacy of kinase inhibitor sorafenib and Hedgehog signaling pathway inhibitors (GANT61 and cyclopamine) against human liver cancer PLC/PRF/5, SMMC7721, and LM3 cells by inhibition of the PI3K/AkT pathway, downregulation of VEGF, MMP-2, MMP-9, and β-catenin, and upregulation of E-cadherin (Sheng et al., 2016; Wang H et al., 2018).